Early serum CA125 response and outcome in epithelial ovarian cancer

Bast, 1983, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med, 309, 883, 10.1056/NEJM198310133091503 Canney, 1984, Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker, Br J Cancer, 50, 765, 10.1038/bjc.1984.254 Krebs, 1986, Role of CA125 as a marker in ovarian cancer, Obstet Gynecol, 67, 473 Niloff, 1985, Predictive value of CA125 antigen levels in second-look procedures for ovarian cancer, Am J Obstet Gynecol, 151, 981, 10.1016/0002-9378(85)90678-7 Atack, 1986, CA125 surveillance and second-look laparotomy in ovarian carcinoma, Am J Obstet Gynecol, 154, 287, 10.1016/0002-9378(86)90657-5 Luesley, 1988, Failure of second-look laparotomy to influence survival in epithelial ovarian cancer, Lancet, ii, 599, 10.1016/S0140-6736(88)90640-X Lavin, 1987, CA125 for the monitoring of ovarian carcinoma during primary treatment, Obstet Gynecol, 69, 223 Vergote, 1987, Evaluation of serum CA125 levels in the monitoring of ovarian cancer, Am J Obstet Gynecol, 157, 88, 10.1016/S0002-9378(87)80352-6 van der Berg, 1988, Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy, Gynecol Oncol, 30, 307, 10.1016/0090-8258(88)90244-2 Serov, 1973, International Classification of Tumours Swenerton, 1985, Ovarian carcinoma: a multivariate analysis of prognostic factors, Obstet Gynecol, 65, 264